ImmunityBio Statistics
Share Statistics
ImmunityBio has 730.16M shares outstanding. The number of shares has increased by 8.34% in one year.
| Shares Outstanding | 730.16M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 4.83% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 75.93M |
| Failed to Deliver (FTD) Shares | 48.16K |
| FTD / Avg. Volume | 0.7% |
Short Selling Information
The latest short interest is 44.41M, so 6.08% of the outstanding shares have been sold short.
| Short Interest | 44.41M |
| Short % of Shares Out | 6.08% |
| Short % of Float | 58.47% |
| Short Ratio (days to cover) | 8.43 |
Valuation Ratios
The PE ratio is -4.38 and the forward PE ratio is -7.86.
| PE Ratio | -4.38 |
| Forward PE | -7.86 |
| PS Ratio | 4105.07 |
| Forward PS | 5.5 |
| PB Ratio | -4.35 |
| P/FCF Ratio | -6.43 |
| PEG Ratio | n/a |
Enterprise Valuation
ImmunityBio Inc. has an Enterprise Value (EV) of 3.17B.
| EV / Earnings | -5.44 |
| EV / Sales | 5098.99 |
| EV / EBITDA | -7.27 |
| EV / EBIT | -8.76 |
| EV / FCF | -7.98 |
Financial Position
The company has a current ratio of 5.05, with a Debt / Equity ratio of -1.16.
| Current Ratio | 5.05 |
| Quick Ratio | 5.05 |
| Debt / Equity | -1.16 |
| Total Debt / Capitalization | 720.82 |
| Cash Flow / Debt | -0.54 |
| Interest Coverage | -2.8 |
Financial Efficiency
Return on equity (ROE) is 0.99% and return on capital (ROIC) is -257.29%.
| Return on Equity (ROE) | 0.99% |
| Return on Assets (ROA) | -1.16% |
| Return on Capital (ROIC) | -257.29% |
| Revenue Per Employee | 925.6 |
| Profits Per Employee | -867.85K |
| Employee Count | 672 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -40.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -38.2% in the last 52 weeks. The beta is -0.43, so ImmunityBio 's price volatility has been lower than the market average.
| Beta | -0.43 |
| 52-Week Price Change | -38.2% |
| 50-Day Moving Average | 4.01 |
| 200-Day Moving Average | 5.02 |
| Relative Strength Index (RSI) | 30.38 |
| Average Volume (20 Days) | 6.92M |
Income Statement
In the last 12 months, ImmunityBio had revenue of 622.00K and earned -583.20M in profits. Earnings per share was -1.15.
| Revenue | 622.00K |
| Gross Profit | 622.00K |
| Operating Income | -362.25M |
| Net Income | -583.20M |
| EBITDA | -436.18M |
| EBIT | -362.25M |
| Earnings Per Share (EPS) | -1.15 |
Balance Sheet
The company has 265.45M in cash and 726.72M in debt, giving a net cash position of -461.27M.
| Cash & Cash Equivalents | 265.45M |
| Total Debt | 726.72M |
| Net Cash | -461.27M |
| Retained Earnings | -2.96B |
| Total Assets | 364.57M |
| Working Capital | 102.19M |
Cash Flow
In the last 12 months, operating cash flow was -366.76M and capital expenditures -30.58M, giving a free cash flow of -397.34M.
| Operating Cash Flow | -366.76M |
| Capital Expenditures | -30.58M |
| Free Cash Flow | -397.34M |
| FCF Per Share | -0.78 |
Margins
Gross margin is 100%, with operating and profit margins of -58.24K% and -93.76K%.
| Gross Margin | 100% |
| Operating Margin | -58.24K% |
| Pretax Margin | -93.87K% |
| Profit Margin | -93.76K% |
| EBITDA Margin | -70.13K% |
| EBIT Margin | -58.24K% |
| FCF Margin | -63.88K% |
Dividends & Yields
IBRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -49.36% |
| FCF Yield | -23.36% |
Analyst Forecast
The average price target for IBRX is $18, which is 672.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $18 |
| Price Target Difference | 672.5% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | -15.26 |
| Piotroski F-Score | 4 |